Clean Watchlist Candidate

MYDAYIS

CNS · ADHD, adults (extended-release mixed amphetamine salts)

MYDAYIS carries product and use-code patents, low complexity (1/5), and no linked clinical competition (0/5). The listed expiry window is approximately 39 months away. Low barriers across both dimensions — a cleaner first-screen candidate worth early IP attention.

Back to watchlist Contact us about this drug

LOE window

39months

to latest listed patent expiry (August 24, 2029)

Expiry attractiveness: 4/5

Patent profile

Substance patent (none)

Product / formulation patent (listed)

Use-code patent (listed)

Patent count: 2

Complexity score: 1/5

Clinical competition

Score: 0/5

Active trials linked: 0

Phase 2/3 trials: 0

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

Applicant (NDA holder): TAKEDA PHARMACEUTICALS USA INC

Confidence: Medium

Market context

Therapeutic area: CNS

Indication: ADHD, adults (extended-release mixed amphetamine salts)

U.S. market size (est.)$100M – $500M

Estimated U.S. net sales tier. Verify current figures before commercial diligence.